An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
Ritesh R. Kotecha, MD
Advertisement
Articles by Ritesh R. Kotecha, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
Progress in the Treatment of Advanced-Stage Classical Hodgkin Lymphoma in the PET-Adapted Era
2
Zipalertinib Yields Early Activity in EGFR+ NSCLC CNS Metastasis Population
3
CRT Does Not Improve RFS/OS, Confers High-Grade Toxicity in Cervical Cancer
4
ctDNA Status May Determine Adjuvant Immunotherapy Benefit in MIBC
5
